PVSRIPO

BIOLOGICAL5 trials

Sponsors

Istari Oncology, Inc., Darell Bigner

Conditions

GlioblastomaInvasive Breast CancerMalignant GliomaMelanoma

Early Phase 1

Examining Bioactivity of PVSRIPO in Invasive Breast Cancer

CompletedNCT03564782

Istari Oncology, Inc.Invasive Breast Cancer

Start: 2019-06-30End: 2022-04-11Updated: 2024-02-08

Phase 1

PVSRIPO for Patients With Unresectable Melanoma

TerminatedNCT03712358

Istari Oncology, Inc.Melanoma

Start: 2018-11-26End: 2021-03-23Updated: 2024-09-19

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

WithdrawnNCT03973879

Darell BignerMalignant Glioma

Start: 2020-02-29End: 2024-01-31Updated: 2020-02-11

PVSRIPO in Combination With Nivolumab in Melanoma

WithdrawnNCT04125719

Darell BignerMelanoma

Start: 2020-06-01End: 2024-10-01Updated: 2020-02-11

Unknown Phase

EAP for the Treatment of Glioblastoma With PVSRIPO

Istari Oncology, Inc.Glioblastoma

Updated: 2022-06-29

Related Papers

Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma

Journal for ImmunoTherapy of Cancer2022-09-0140 citations

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

Journal for ImmunoTherapy of Cancer2021-04-0177 citations

302 A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma

Regular and Young Investigator Award Abstracts2020-11-016 citations